Global Congress on
Nephrology and Kidney Health
May 20–21, 2027 | Paris, France
30+ Years of Management Experience
Paris, France
Phone: +44 2045874848
WhatsApp: +44 7429481517

Nephrology Congress 2027

Home › Scientific Program
Amani Smiai
Amani Smiai

University Hospital Center "Habib Bougatfa" of Bizerte, Tunisia

Title : Impact of dapagliflozin on arterial stiffness in chronic heart failure: Pulse wave velocity assessed by photoplethysmography

Abstract:

Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are recommended in chronic heart failure (CHF) for their cardioprotective and nephroprotective effects. The aim of our study was to evaluate their impact on arterial stiffness, assessed by finger-toe pulse wave velocity (ftPWV) using photoplethysmography.

Methods: This was a prospective, single-center study including patients followed for SGLT2i-naïve CHF, from April 2024 to March 2025. ftPWV was assessed at baseline and after 6 months after dapagliflozin initiation.

Results: Forty-one patients were included (mean age = 62.78 years, sex ratio = 4.8). CHF was predominantly ischemic (37 patients) with reduced left ventricular ejection fraction (LVEF) in 19 cases. Chronic kidney disease (CKD) was present in 17 cases.

The mean ftPWV was 8.77m/s, with accelerated vascular aging observed in 30 patients. Arterial stiffness was correlated with age, CHF class, body mass index (BMI), anemia, hematocrit, hyperuricemia, LVEF, E/E’ ratio, low cardiac output, shortened transit time, and systolic pressure index. In multivariate analysis, anemia (OR=0.062) and hematocrit (OR=2.927) were independently associated with arterial stiffness.

After 6 months, ftPWV significantly decreased from 8.77 to 7.43m/s (p=0.5E-5), corresponding to a vascular age improvement of 13.4 years. This reduction was correlated with CHF class (p=0.017), mineralocorticoid receptor antagonists (MRA) (p=0.009), BMI (p=0.03), hematocrit (p=0.033), serum uric acid (p=0.022), serum calcium (p=0.019), left ventricular end-diastolic volume (p=0.022), LVEF (p=0.012), cardiac output (p=0.046), deceleration time (p=0.023), and central systolic (p=0.04) and diastolic (p=0.02) pressures. In multivariate analysis, MRA, serum uric acid and central systolic pressure were independently associated with improvement in arterial compliance.

Conclusion: SGLT2i significantly improve arterial stiffness in patients with CHF. These findings support their potential role in optimizing CHF management and improving patient outcomes.

Biography:

Updating soon...